SCHEMBL6492811

SCHEMBL6492811

CC(C)(C)c1ccc(CNc2cccc3c2oc2ccccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
EGFR P00533 3/20 0.40
IGF1R P08069 3/20 0.40
KDR P35968 3/20 0.40
FLT4 P35916 2/20 0.40
EPHX2 P34913 1/20 0.40
LMNA P02545 2/20 0.39
RAB9A P51151 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6494308 0.82 EGFR (0.59) HPGDHTTMEN1KMT2AKDM4E
SCHEMBL6493932 0.80 ADRA2C (0.55) HPGDHTTHSD17B10MEN1KMT2A
SCHEMBL29735962 0.80 ALDH1A1 (0.42) HPGDHTTHSD17B10MEN1KMT2A
SCHEMBL16185361 0.80 ALDH1A1 (0.42) HPGDHTTHSD17B10MEN1KMT2A
SCHEMBL31685986 0.80 ALDH1A1 (0.42) HPGDHTTHSD17B10MEN1KMT2A
SCHEMBL29188257 0.77 ALDH1A1 (0.64) HPGDHSD17B10MEN1KMT2AKDM4E
SCHEMBL6484020 0.76 CA1 (0.45) HPGDHTTHSD17B10MEN1KMT2A
SCHEMBL6495698 0.75 ABCB1 (0.52) HPGDHTTHSD17B10MEN1KMT2A
SCHEMBL6495828 0.75 HPGD (0.44) HPGDHTTHSD17B10MEN1KMT2A
SCHEMBL6483726 0.74 ABCB1 (0.56) HPGDMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 HPGD 3199/4885HTT 4405/4885HSD17B10 1886/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 HPGD 4074/4885HTT 3494/4885HSD17B10 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.